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Bone mineral density and biochemical markers of bone turn- Chronic renal failure (CRF) is associated with skeletal
over in patients with predialysis chronic renal failure. abnormalities known as renal osteodystrophy (ROD),
Background. Metabolic bone disease might commence early including different types of bone tissue abnormalitiesin the course of renal failure. This study therefore examined
when evaluated by histomorphometry [1].the frequency and severity of the skeletal changes in predialysis
Osteopenia is a frequent feature that may lead to fra-chronic renal failure by measurements of bone mineral density
(BMD), biochemical markers of bone turnover (osteocalcin, gility fractures late in the course of ROD [2]. Patients
bone-specific alkaline phosphatase, carboxy terminal propep- with mild to moderate degrees of CRF rarely experience
tide of type I collagen, and carboxy-terminal telopeptide of symptoms. However, recent studies have shown that moretype I collagen), parathyroid hormone (PTH), ionized calcium
than 50% of patients with only moderate renal failure(Ca11), phosphate (P), and vitamin D metabolites.
have abnormal bone histology [1, 3], indicating that skel-Methods. The study was performed in 113 patients (male/
female: 82/31) with chronic renal diseases [mean glomerular etal changes may be initiated years before the symptoms
filtration rate (GFR) of 37 ml/min] and in 89 matched, normal arise and at least in some patients at very early stages
control subjects. of CRF.Results. The patients had significantly (P , 0.05) reduced
Bone mineral density (BMD) measured by dual-energyBMD in the spine (26.3%), the femur (212.1%), the forearm
x-ray absorptiometry (DEXA) has proven to be a strong(25.7%), and the total body (24.2%) as compared with the
control subjects. Dividing the patients into quartiles according predictor of bone strength in healthy persons and in osteo-
to GFR revealed that BMD decreased with the gradual decline porotic patients [4, 5], and DEXA is a precise, rapid,
in renal function at all the measured skeletal sites, but was most and noninvasive procedure to detect osteopenia [6, 7].pronounced in the femur: 0.63 6 0.03, 0.74 6 0.02, 0.77 6 0.02,
Most studies on BMD in patients with renal failure thatand 0.82 6 0.03 g/cm2 in each quartile from lowest to highest
have been published during the recent years have beenGFR compared with 0.82 6 0.02 g/cm2 in the control group (P ,
0.0001). All of the measured bone markers showed increasing performed in patients on dialysis, where several investi-
plasma levels with the more advanced stages of renal failure. gators have found reduced bone mass [8–14]. Studies on
Serum PTH and serum P levels increased, whereas serum Ca11 BMD in patients with mild to moderate CRF are few.and 1,25-dihydroxyvitamin D decreased. BMD Z-scores of the
Most of the cohorts are small, and the inclusion criteriafemur and of the forearm correlated to the biochemical markers
differ in terms of the underlying renal diseases and theand to PTH (P , 0.05 to P , 0.0001). The biochemical markers
all showed strong correlations to PTH, also when corrected severity of the renal impairment [11, 15–18]. Further-
for the effect of the decline in GFR (r 5 0.40 to 0.92, P , 0.01 more, the bone mineral measurements have been per-
to P , 0.0001). formed by the use of different techniques [single- or dual-Conclusion. Skeletal changes are initiated at an early stage
energy photon absorptiometry (SPA/DPA) or DEXA]of chronic renal failure, as estimated from reduced BMD and
measuring at different parts of the skeleton and usingelevated levels of PTH and from the biochemical markers of
both bone formation and bone resorption. different control groups, all of which might explain the
different results obtained. Reduced BMD of the appen-
dicular skeleton has been found in several investigationsKey words: BMD, biochemical bone markers, parathyroid hormone,
[8, 16, 18], whereas BMD of the axial skeleton might bemetabolic bone disease, skeleton, renal osteodystrophy, osteopenia,
dialysis. reduced [17] or unchanged [16].
An attempt to evaluate ROD biochemically has gener-Received for publication April 21, 1998
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(AP), and the vitamin D status. However, currently, bio- markers. Group 1 (GFR 6 to 26 ml/min) represented
patients with the most advanced stages of renal failure.chemical markers of bone turnover are being evaluated
in the diagnosis and monitoring of metabolic bone disease Groups 2 (GFR 27 to 47 ml/min) and 3 (GFR 47 to 69
ml/min) represented patients with moderate and mild[18]. Among these, osteocalcin, carboxy terminal pro-
peptide of type I collagen (PICP), and bone-specific AP renal impairment, respectively, whereas group 4 (GFR
71 to 110 ml/min) was established from a group of pa-(BAP) reflect bone formation, whereas carboxy-terminal
telopeptide of type I collagen (ICTP) reflects bone re- tients with a serum creatinine level above the upper
normal range (130 mmol/liter), but who had a GFRsorption.
The usefulness of these new potential markers of bone within the normal range when the creatinine clearance
was measured. Group 5 represented the control subjects.turnover in patients with renal failure has not been clari-
fied, although a few studies have shown a good correla- The patients in group 1 had a lower body mass index
(BMI) of 24 6 4 kg/m2 compared with the other patienttion between some of the bone markers and some of
the histomorphometric parameters of bone turnover in groups, in which BMI was 27 6 5 kg/m2. There was no
difference in age between the groups. In groups 1patients on maintenance dialysis [19, 20].
This study was designed further to examine the fre- through 3, females constituted 29, 35, and 35% of the
patients, respectively, whereas only 14% of the patientsquency and severity of the skeletal demineralization in
patients with predialysis CRF by measurements of the in group 4 were women.
Twenty-two patients with insulin-dependent diabetesBMD in different skeletal regions (trabecular and corti-
cal bone) and by evaluation of the serum levels of osteo- were included and equally distributed between groups 1
through 3, whereas there were fewer diabetic patientscalcin, PICP, BAP, and ICTP in patients with mild to
moderate CRF as compared with these measures of bone in group 4.
The control group of healthy subjects (N 5 89, group 5)metabolism in a healthy control group.
was chosen to match the patient group with regards to
gender, age (within 5 years for women and within 10
METHODS
years for men), and body weight (65%) in order to
The study design was cross-sectional. Patients were eliminate the effect of these three major determinants
recruited from the outpatient clinics at three Danish on the BMD, which are unrelated to the renal disease
County Hospitals. All hospital records of patients fol- [21, 22]. Healthy subjects were recruited among hospital
lowed at the nephrological departments were evaluated, staff along with their relatives and friends. The study
and patients with a serum creatinine value above 130 was approved by the regional committee of ethics. All
mmol/liter (upper normal range) were invited to partici- participants gave their written informed consent.
pate, unless exclusion criteria were met. Exclusion crite-
Bone density measurementsria included: patients with acute renal failure, patients
receiving maintenance dialysis, kidney transplanted pa- Bone mineral density of the lumbar spine (L2 through
tients, patients who currently were taking or who within L4) in the anteroposterior projection, the femoral neck,
the last five years had been taking medication known to the distal forearm, and the total body were determined
influence bone metabolism [such as corticosteroids, other by DEXA on a QDR2000 bone densitometer (Hologic
immunosuppressive agents, hormone replacement ther- Inc., Waltham, MA, USA) expressed as exact values in
apy (HRT), vitamin D analogs, anticoagulants, or lithium], g/cm2 and as Z scores, which represent the BMD value
and bedridden patients. Thus, several patients with glo- normalized for age- and sex-matched mean, or as T
merulonephritis (immunosuppressive therapy) and sev- scores that refer to the young adult reference mean calcu-
eral female patients (HRT) had to be omitted. Four hun- lated from the manufacturer’s database of 400 males and
dred hospital records were evaluated. One hundred and 900 females. Coefficients of variation at our clinic are
fifty patients were contacted, and 128 agreed to partici- 0.9% at the lumbar spine, 1.9% at the femoral neck,
pate. Fifteen had to be excluded because of the presence 1.0% at the distal forearm, and 0.8% for the whole-body
of one or more exclusion criteria, and therefore, 113 pa- scan.
tients (31 females of whom 16 were postmenopausal and
Biochemical measurements82 males), all Caucasian, were included. None of the pa-
tients were on a protein-restricted diet, and none received Blood samples were drawn after an overnight fast be-
phosphate binders at the time of the investigation. tween 8 and 10 a.m. Urine was collected for 24 hours in
The demographic data of the patients are presented order to calculate the creatinine clearance rates. Serum
in Table 1. The patients were stratified into quartiles samples for determination of biochemical bone markers
according to the glomerular filtration rate (GFR) in or- were stored at 2808C until analysis. GFRs were assessed
der to examine the influence of increasing impairment by a 24-hour creatinine clearance value. Serum Ca11
and serum P were measured using routine laboratoryof the renal function on BMD and the biochemical bone
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Table 1. Clinical features of patients with chronic renal failure stratified into quartiles by GFR and of the control group
Patient quartiles Controls
Group 1 2 3 4 5
N 28 28 28 29 89
Gender f/m 10/18 8/20 8/20 4/24 30/59
Age years 59 (14) 55 (13) 54 (12) 53 (13) 56 (12)
BMI kg /m2 25 (5) 27 (5) 27 (6) 27 (5) 26 (6)
Mean GFR ml/min 16 (6) 39 (8) 58 (10) 86 (19) 144 (54)
Underlying renal disease
IDDM 3 (10) 7 (24) 9 (29) 2 (7) —
NIDDM 11 (38) 6 (21) 5 (16) 4 (14) —
Glom. nephr. 5 (17) 6 (21) 5 (16) 2 (7) —
HKD 2 (7) 6 (21) 2 (6) 8 (29) —
PKD 5 (17) 1 (3) 4 (13) 8 (29) —
Miscellaneous 3 (10) 3 (10) 6 (19) 4 (14)
Abbreviations are: BMI, body mass index; HKD, hypertensive kidney disease; PKD, polycystic kidney disease; Miscellaneous, congenital malformations, Alport
syndrome, gout- and drug-induced nephropathy, unknown cause. Values are means 6 sd or N (%).
procedures. All biochemical bone markers were mea- between groups. Bivariate correlations were performed in
log-transformed data. A forward stepwise regressionsured by the Bone and Mineral Research Group (Aarhus
University Hospital, Aarhus, Denmark). analysis was used to detect predictors of BMD [26].
Statistical analyses were performed using the softwareIntact PTH was measured by a radioimmunoassay (Al-
legro Intact PTH, IRMA; Nichol’s Institute, San Juan, Stat View 4.5 (Abacus Concepts, Berkeley, CA, USA).
Capistrano, CA, USA). The intra-assay coefficient of vari-
ation (CV) was 2.6%, and the interassay CV was 5.8%.
RESULTS
Serum 25-hydroxyvitamin D was measured by a radio-
Bone mineral densityimmunoassay (Incstar Kit 60160; Incstar Corp., Stillwa-
ter, MN, USA) after acetonitrile extraction. Intra-assay Bone mineral density was reduced at all areas of the
skeleton examined, when all the patients were comparedand interassay CVs were 8 and 15%, respectively. Serum
1,25-dihydroxyvitamin D was extracted by acetonitrile, with the matched control group. The difference in BMD
at the site of the lumbar spine was 26.3% (0.98 6 0.02purified through a C18-OH reverse phase column, and
finally measured by a radioimmunoassay (Nichols-Kit vs. 1.04 6 0.02 g/cm2, P , 0.05); the femoral neck, 212.1%
(0.72 6 0.01 vs. 0.82 6 0.02, P , 0.0001); the distal40-6040). The intra-assay and interassay CVs were 6.5
and 13.2%. forearm, 25.7% (0.68 6 0.01 vs. 0.72 6 0.01, P , 0.05);
and the total body, 24.2% (1.08 6 0.01 vs. 1.12 6 0.01,Serum cross-linked ICTP was measured by an equilib-
P , 0.05).rium radioimmunoassay from Orion Diagnostics (Espoo,
When the patients were separated into quartiles ac-Finland). Intra-assay and interassay CVs were 5 and 6%
cording to the degree of renal failure, it was found that[23]. The PICP was measured by an equilibrium RIA
BMD decreased in relationship to the decrease in GFR(Orion Diagnostics), with an intra-assay and interassay
at all measured sites, as shown in Figure 1.CV of 3 and 5%, respectively. Serum AP was measured
The greatest differences between the patient groupsspectrophotometrically using serum nitrophenylphos-
and the control group were found at the site of the femurphate as the substrate according to recommendations
where significant differences in between patient groupsfrom the Scandinavian Committee on Enzymes [24]. In-
(P , 0.05), as well as between patients and control sub-tra-assay and interassay CVs were 1.8 and 3%, respec-
jects (P , 0.05), were found. At the levels of the lumbartively. BAP was measured spectrophotometrically in the
spine, the distal forearm and the total body significantsupernatant after lectin precipitation. The intra-assay
differences (P , 0.05 to P , 0.001) were identified be-and interassay CVs were 8 and 25%. Serum osteocalcin
tween the lowest GFR quartile (group 1) and the controlwas determined by a radioimmunoassay using rabbit anti-
group (group 5).serum against bovine bone gla protein. The intra-assay
The prevalence of osteoporosis as defined by theand interassay CVs were 5 and 10% [25].
World Health Organization (a T score of less than 22.5)
Statistical analysis was significantly increased (P , 0.0001) in the patient
group (30%) as compared with the control group (10%)Students unpaired t-test was used to evaluate the differ-
ences between patients and control subjects. Analysis of vari- and even more so in the patients with the more advanced
stages of renal failure (Table 2).ance or the Kruskal–Wallis test was used to test differences
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Fig. 1. Bone mineral density (BMD) in patients with chronic renal
failure who were divided into quartiles according to glomerular filtration
Fig. 2. Bone mineral density (Z-scores) of patients with a debut of arate (GFR) measurements in comparison to normal control subjects.
chronic renal disease before 30 years of age compared to patients withSymbols are: (d) group 1, mean GFR 16 ml/min; (m) group 2, mean
a debut when they are 30 years or older. Symbols are: (j) early debut;GFR 39 ml/min; (j) group 3, mean GFR 58 ml/min; (r) group 4, mean
( ) later debut. *P , 0.05, by Student’s t-test.GFR 83 ml/min; (s) group 5, control group, mean GFR 144 ml/min.
*P , 0.05, **P , 0.001, and ***P , 0.0001, by ANOVA.
Table 2. Distribution of bone mineral density (BMD) T-scores , 22.5 of patients divided according to the severity of chronic renal failure
and of the control group
Patient groups
1 2 3 4 All patients Controls
T-score , 22.5 (N 5 28) (N 5 28) (N 5 28) (N 5 29) (N 5 113) (N 5 89)
Spine 27a 24 6 7 19b 8
Hip 42a 26 13 4 26c 2
Distal forearm 55a 24 20 14 33c 10
Spine and/or hip 30c 10
Values are given in percentages of the respective patient groups (group 1, mean GFR 16; group 2, 39; group 3, 58; and group 4, 86 ml/min). A T-score , 22.5
defines osteoporosis according to WHO criteria.
a P , 0.05 group 1 compared to group 3; b P , 0.05; c P , 0.0001, all patients compared to controls
The possible impact of the age at onset of CRF on Parameters of calcium homeostasis
BMD was examined by dividing all the patients into two Patients with predialysis CRF exhibited several abnor-
groups according to the onset of the renal disease before mal parameters involved in the bone metabolism, as
or after the age of 30 years, which is the age of peak compared with their matched controls.
bone mass [27]. The results were expressed as Z scores As shown in Figure 4, serum PTH and P levels in-
(Fig. 2) in order to account for the differences in current creased significantly (P , 0.05) with the decline in GFR,
age and sex between the two groups. Patients with an whereas serum Ca11 decreased (P , 0.05), with the
early debut of the renal disease had significantly reduced lowest circulating levels found in patients with the most
BMD as compared with patients with a debut of the severe degree of renal impairment. The serum levels of
disease later in life at the sites of the lumbar spine, the 1,25-dihydroxyvitamin D were also reduced (P , 0.05)
femoral neck, and the distal forearm. in the advanced stages of CRF.
When dividing the study group according to whether
Biochemical markers of bone turnoverthe patients had insulin-dependent diabetes mellitus
(IDDM) or other kidney diseases, it was found that the The mean serum levels of the different biochemical
combination of impaired renal function and IDDM en- markers of bone formation (osteocalcin, PICP, and BAP),
hanced the risk of low BMD, as illustrated in Figure 3. as well as of bone resorption (ICTP), all increased with
The BMD Z scores of the femoral neck and of the distal the more advanced stages of renal impairment. Signifi-
forearm were significantly reduced in the group of pa- cantly increased (P , 0.05) serum values of osteocalcin,
tients with IDDM, as compared with patients with differ- BAP, PICP, and ICTP were found in the group of pa-
ent chronic renal diseases, whereas the BMD of the tients with the most advanced stages of renal failure
when compared with the control group (Fig. 5).lumbar spine was not significantly reduced.
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Fig. 3. Bone mineral density (Z-scores) of patients with insulin-depen-
dent diabetes mellitus (IDDM; j) compared to patients with other
chronic renal diseases ( ). *P , 0.05, by Student’s t-test.
Bivariate correlations between the biochemical bone
markers and PTH and GFR are shown in Table 3. A
strong positive correlation (P , 0.0001) was demonstrated
between PTH and the bone markers osteocalcin, BAP,
and ICTP, whereas the correlation to PICP was not sig-
nificant. A significant inverse correlation (P , 0.0001)
was found between PTH and GFR. Each of the measured
bone markers was negatively correlated to GFR (P ,
0.05 to P , 0.001). To further examine the relationship
between PTH and the bone markers, a partial correlation
analysis was performed. The correlation between PTH
and the bone markers remained significant after the ad-
justment for the influence of GFR: osteocalcin, r 5 0.89,
P , 0.0001; BAP, r 5 0.69, P , 0.0001; ICTP, r 5 0.64,
P , 0.0001; and PICP, r 5 0.27, P , 0.05.
In order to examine the effect of the serum levels of
PTH on BMD, patients were divided into three groups
according to the degree of secondary hyperparathyroid-
ism: Serum PTH increased to more than two times above
normal limits (120 pg/ml), serum PTH between 60 and
120 pg/ml, and serum PTH within normal reference
range (,60 pg/ml). A negative association between the
degree of secondary hyperparathyroidism and BMD was
found at the sites of the lumbar spine, the hip, and the
total body, but not in the arm, and the patients who had
the most severe degrees of secondary hyperparathyroid-
ism had the most reduced levels of BMD as compared
with the patients with PTH levels within the normal
reference range (Fig. 6).
To examine the importance of the different risk factors
for reduced BMD, a forward stepwise regression analysis
was performed with BMD of the hip given in Z scores
as the dependent variable and BMI, creatinine clearance
rates, serum PTH, and the duration of and age at onset Fig. 4. Parameters of calcium homeostasis in patients with chronic renal
failure divided into quartiles according to glomerular filtration rate (GFR)of the renal disease as independent variables. BMI and
compared to control subjects. Symbols are: (d) group 1, mean GFR 16creatinine clearance rates were the two variables that
ml/min; (m) group 2, mean GFR 39 ml/min; (j) group 3, mean GFR 58
significantly predicted BMD, accounting for 19% of the ml/min; (r) group 4, mean GFR 83 ml/min; (s) group 5, control group,
mean GFR 144 ml/min. *P , 0.05, Kruskal-Wallis test.variation (R2 5 0.19, P , 0.001) in BMD, and each of the
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Table 3. Correlations between biochemical bone markers,
PTH and GFR
logPTH logBGP logICTP logBAP logPICP
GFR 20.62b 20.58b 20.64b 20.34a 20.24a
LogPTH — 0.80b 0.60b 0.49b 0.19
LogBGP — — 0.67b 0.52b 0.47b
LogICTP — — — 0.49b 0.35a
LogBAP — — — — 0.53b
a P , 0.05, b P , 0.0001
Fig. 6. Bone mineral density (BMD; Z-scores) in patients with chronic
renal failure divided according to the degree of secondary hyperparathy-
roidism. Patients were divided into three groups: serum parathyroid
hormone (PTH) , 60 pg/ml (j); serum PTH between 60 and 120 pg/ml
( ); serum PTH . 120 pg/ml ( ). *P , 0.05, Student’s t-test.
two variables contributed equally [standard coefficients
(standard errors) of 0.24 (0.03) and 0.30 (0.006)]. Serum
PTH and duration and age at onset of the renal disease
were not significant predictors in this type of analysis.
DISCUSSION
In this group of 113 patients with predialysis CRF,
BMD was reduced in the axial, as well as in the appendic-
ular skeleton, indicating that both cortical bone and tra-
becular bone were affected. The prevalence of overt
osteoporosis (T-score , 22.5) was found to be increased
when compared with healthy sex-, age-, and weight-
matched controls. The study included patients ranging
from mild to severe degrees of renal failure, and the
decrease in BMD was most pronounced in patients withFig. 5. Biochemical markers of bone turnover in patients with chronic
the lowest levels of GFR. Debut of the renal diseaserenal failure divided into quartiles according to GFR compared to
normal control subjects. Symbols are: (d) group 1, mean GFR 16 ml/ before skeletal maturity was reached and diabetic ne-
min; (m) group 2, mean GFR 39 ml/min; (j) group 3, mean GFR 58 phropathy further increased the risk of low BMD. In aml/min; (r) group 4, mean GFR 83 ml/min; (s) group 5, control group,
multivariate analysis, GFR and BMI were the strongestmean GFR 144 ml/min. *P , 0.05, Kruskal-Wallis test.
predictors of BMD.
Secondary HPT, reduced levels of serum Ca11 and
serum 1,25-dihydroxyvitamin D, and increased serum
levels of P were evident in the patients with moderate
to severe degrees of renal failure.
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The biochemical markers of bone turnover (osteocal- commence at an early stage of renal failure. Bianchi
et al reported that patients with predialysis CRF havecin, ICTP, PICP, and BAP) all exhibited elevated serum
levels in the patient groups with the more advanced reduced BMD levels that correlate to the reduction in
GFR [16]. However, they concluded that only corticalstages of renal failure corresponding to the degree of
secondary HPT. Adjusting the correlation between PTH bone was affected, which is in disagreement with the
present results showing that trabecular and cortical boneand the different biochemical bone markers for the in-
fluence of GFR did not change the results, indicating are equally affected in these uremic patients. Reasons
for this discrepancy might be due to different scanningthat the increased levels of the different biochemical
bone markers might indeed represent increased bone techniques and different patient groups.
It has been proposed that the duration of the renalturnover caused by the secondary hyperparathyroidism
and not just caused by retention of the substances. The disease might be an important risk factor for low BMD.
In dialysis patients, some studies showed a negative corre-presence of advanced secondary HPT (serum PTH .
120 pg/ml) was associated with decreased BMD. lation between time on dialysis and BMD [11, 12], whereas
others failed to prove such a correlation [8, 9, 37]. In thoseWhether BMD measurement is an appropriate tool
in the diagnosis and/or monitoring of renal bone disease studies, the duration of the predialysis phase of the renal
disease was not considered, which from our investigationis still a matter of debate. DeVita et al concluded from
a study comparing histomorphometric results to DEXA seems to be of importance when evaluating renal bone
disease. Further support for this argument was suppliedresults that the sensitivity of BMD measurements was
poor [20]. Furthermore, Malluche and Faugere pointed by Heaf, Hielsen, and Mogensen, who, in a group of
patients followed from predialysis to dialysis stages ofout that DEXA measurements did not separate the dif-
ferent types of ROD (high turnover, low turnover, and their renal disease, found that some of the patients with
the lowest BMD at the time when dialysis treatment wasmixed uremic osteodystrophy), which may be essential
for the choice of treatment [28]. However, the severity commenced actually gained bone mass within one year,
perhaps because of the improvement in the uremic stateof the symptoms of ROD may not correlate with the
histological changes, as some patients have severely ab- or because of supplementation with 1,25-dihydroxy-vita-
min D [8].normal bone histology and no symptoms and vice versa
[2]. Patients with reduced bone mass are at great risk of Therefore, when considering the initiation and the
early stages of ROD, the predialysis period seems asexperiencing fractures, the most severe consequence of
ROD, and this part of the population at risk can be important as the end-stage period.
It has been suggested that the underlying renal diseasedetected by DEXA measurements. This investigation
has shown that even in predialysis stages of CRF, a may have some influence on the severity of the renal
bone disease. Cundy et al, in a study on histomorphome-substantial proportion of the patients, patients who
would not be considered for bone biopsies in the daily tric changes in predialysis patients, demonstrated that
tubulointerstitial renal diseases affect the skeleton moreclinic, showed signs of disturbed bone metabolism as
measured by noninvasive methods. than glomerulovascular diseases and suggested that this
might be due to more pronounced changes of the calciumSpecific biochemical markers of bone turnover have
been studied extensively over the last decade, but the homeostasis caused by the former group of diseases [38].
This is in opposition to the results of others in whichactual concept in the bone research field is that these
biochemical markers are of no certain diagnostic use in patients with diabetic nephropathy [15, 39] have been
found to have increased risk of renal bone disease. It isthe single patient, but might be of some use in following
the results of clinical trials [29, 30]. The reasons for the not clear, however, whether the diabetic state or the
renal complication is the most important factor, as otherslimitation in the daily clinical use are a substantial intra-
individual variability [31] and a poor correlation between have shown that IDDM by itself is a risk factor for
reduced BMD [40, 41], whereas patients with NIDDMthe markers and the rate of bone loss [32].
Only a few publications exist on the use of biochemical have normal or even increased BMD [42]. Furthermore,
Moorhead et al found that patients with polycystic kid-bone markers in patients with predialysis CRF. In those,
it was concluded that the retention of the bone markers ney disease were less susceptible to bone changes than
patients with other renal diseases [43].osteocalcin and ICTP caused by the reduced renal clear-
ance [23, 33] introduced an error, which made it difficult In this study, IDDM but not NIDDM was found to
be a risk factor for low BMD, whereas the patient groupsto interpret the results. The clearance of PICP and BAP
is not by the kidney, but takes place in the liver, which with other renal diseases each comprised numbers of
patients that were too limited to be evaluated separately.may render these markers more suitable in the evalua-
tion of renal bone disease [34, 35]. Reduced BMD has been demonstrated in children and
adolescents with CRF [44]. This is in accordance withThe results of this study support the findings from
histomorphometric studies [3, 8, 36] that skeletal changes the results of this investigation, where it appears to be of
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importance whether chronic renal disease occurs before skeleton, a state that may or may not have been estab-
lished long enough to have caused substantial bone loss.skeletal maturity is reached, suggesting that patients with
a debut of the renal disease before adulthood may not Despite the obvious adverse effects on BMD of the
different aspects of CRF that were evaluated in thisachieve an adequate peak bone mass and, therefore,
have an increased risk of developing osteopenia when study, a considerable variation in BMD exists within this
group of patients. The contribution of other factors suchfactors causing accelerated bone loss appear.
The secondary hyperparathyroidism and low serum as heritage, hormonal status, and physical activity is pos-
sible. The advantage of a longitudinal study as opposedlevels of 1,25-dihydroxyvitamin D, which become evi-
dent in end-stage renal failure, have been shown to be to the cross-sectional design used in this study is there-
fore obvious, and long-term prospective studies withinitiated at early stages of the renal disease [45, 46],
which corroborate with the results of this study. skeletal symptoms and fragility fractures as efficacy end-
points are needed to validate the predictive value ofThe elevated levels of the biochemical bone markers
found in this study are in accordance with results from these noninvasive methods in relationship to symptom-
atic bone disease in patients with CRF.a few other studies performed in predialysis patients in
which the bone formation markers osteocalcin [47], BAP In conclusion, a state of high bone turnover resulting
in reduced bone density is present early in the course of[48], and PICP [34] have been evaluated. Elevated serum
levels of the bone markers have been reported consis- CRF (GFR 6 to 70 ml/min), as estimated from reduced
BMD levels, elevated serum PTH, reduced 1,25-dihy-tently in patients receiving maintenance dialysis [31, 48–52],
but in these patients with none or very little remaining droxyvitamin D levels, and the elevated levels of bio-
chemical markers of both bone formation (osteocalcin,kidney function, the accumulation of substances may be
pronounced. PICP, BAP) and bone resorption (ICTP). This study
further demonstrates that useful information on the boneThe apparent lower serum concentrations of PICP and
BAP in the patients with incipient renal failure (group 4) status can be obtained by using noninvasive methods,
such as BMD measurements and biochemical markersmay be coincidental, as there was no significant differ-
ence from the values of the control group, or it may be of skeletal formation and resorption in patients with
predialysis CRF.due to the fact that this group consisted almost exclu-
sively of male subjects, who may have lower values of
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